NASDAQ · APRE
Healthcare · Biotechnology
$0.73
Up+$0.02 (+2.67%)
Updated Sep 17, 2026, 11:48 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
APRE closed at $0.73 after 20 trading sessions, up 8.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $0.729 | $0.757 | $0.7111 | $0.7305 | 186K |
| Sep 15, 2026 | $0.82 | $0.82 | $0.7333 | $0.7488 | 184.18K |
| Sep 14, 2026 | $0.771 | $0.8427 | $0.76 | $0.7814 | 120.27K |
| Sep 11, 2026 | $0.7957 | $0.8199 | $0.7651 | $0.774 | 127.72K |
| Sep 10, 2026 | $0.7805 | $0.8101 | $0.7805 | $0.7892 | 61.33K |
| Sep 9, 2026 | $0.85 | $0.871 | $0.7832 | $0.7914 | 135.46K |
| Sep 8, 2026 | $0.8403 | $0.88 | $0.7788 | $0.835 | 323.72K |
| Sep 4, 2026 | $0.80 | $0.8092 | $0.7914 | $0.7943 | 90.48K |
| Sep 3, 2026 | $0.82 | $0.82 | $0.7802 | $0.8063 | 112.97K |
| Sep 2, 2026 | $0.8101 | $0.854 | $0.7986 | $0.82 | 170.56K |
| Sep 1, 2026 | $0.78 | $0.90 | $0.7795 | $0.8357 | 465.71K |
| Aug 31, 2026 | $0.8454 | $0.8517 | $0.78 | $0.80 | 479.83K |
| Aug 28, 2026 | $0.88 | $0.9099 | $0.8202 | $0.8386 | 346.18K |
| Aug 27, 2026 | $0.99 | $0.99 | $0.81 | $0.8601 | 1.18M |
| Aug 26, 2026 | $1.09 | $1.16 | $0.923 | $0.98 | 2.82M |
| Aug 25, 2026 | $0.815 | $0.99 | $0.8025 | $0.9499 | 2.15M |
| Aug 24, 2026 | $0.7042 | $0.85 | $0.6801 | $0.8052 | 2.8M |
| Aug 21, 2026 | $0.6565 | $0.6697 | $0.623 | $0.6403 | 14.85K |
| Aug 20, 2026 | $0.6721 | $0.6926 | $0.6328 | $0.6401 | 38.86K |
| Aug 19, 2026 | $0.6948 | $0.71 | $0.668 | $0.671 | 52.71K |
The latest Smart Investors Daily articles mentioning APRE.
APRE research
Company profile and research snapshot.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wedbush | Outperform | — |
| May 14, 2026 | Wedbush | Outperform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Mar 31, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with
Benzinga · Aug 27, 2026
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock increased by
Benzinga · Jul 30, 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
Benzinga · Mar 3, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APRE.
